|
|
|
|
|
HONG KONG, Mar 10, 2016 - (ACN Newswire) - One of the largest comprehensive marketing, promotion and channel management service providers dedicated to imported pharmaceutical products and medical devices in China, China Pioneer Pharma Holdings Limited ("China Pioneer Pharma" or the "Company" or the "Group"; HK:1345), is pleased to announce that a UNITY Balloon Expandable Bioresorbable Hybrid Biliary / Peripheral Vascular Stent, a medical device produced by QualiMed Innovative Medizinprodukte GmbH ("QualiMed"), was implanted successfully for the first time in Southeast Asia. China Pioneer Pharma is the distributor of QualiMed's medical products for vascular disease treatment in mainland China and throughout Southeast Asia. The company also owns about 36.57% shares of Q3 Medical Devices Limited, which is the holding company of QualiMed.
The novel UNITY Balloon Expandable Bioresorbable Hybrid Biliary/Peripheral Vascular Stent combines a bioresorbable magnesium center and a bioresorable polymer outer. It is a device that will disappear over time and could eliminate the removal procedure significantly reducing the cost and complications associated with such surgeries. After the completion of the first in man study, QualiMed will initiate a similar trial for peripheral indications and expects to conduct its trial for coronary procedures in the second half of 2016. The UNITY Biliary approval is forecasted for the 2nd half of 2016, followed by UNITY Peripheral, and UNITY Coronary devices respectively.*
Mr. LI Xinzhou, Chairman and Executive Director of China Pioneer Pharma said: "This is a significant milestone not only for the QualiMed but also for the medical field. Compared with the traditional plastic stent, biodegradable implants will improve efficacy and eliminate cost for the patients, care givers, and insurance providers. As the exclusive distributor of QualiMed's medical products for vascular disease treatment throughout Southeast Asia, we believe this breakthrough will improve the Medical and health care industry remarkably.
*QualiMed release, Feb 11, 2016: http://www.qualimed.de/news/UNITY_Implanted_in_Asia.pdf
About Q3 Medical Devices Limited
Q3 Medical Devices Limited is an Irish based holding company with multiple operations in Germany. The holding and its subsidiary companies are focused on the development, manufacturing and distribution of minimally invasive devices for the treatment of patients with cardiology, peripheral vascular and non-vascular diseases. For more information, please visit www.q3medical.com.
About QualiMed
QualiMed, a wholly owned subsidiary of Q3 Medical, was founded in 1997 in Winsen, Germany near Hamburg, where it develops, manufactures and sells implantable medical devices in the Cardiology, Peripheral Vascular, and Non Vascular areas. The innovations are focused in the areas of Biodegradable Products, Drug Device Combination Technologies, Catheter and Mechanical implant areas. For more information, please visit www.qualimed.de.
About China Pioneer Pharma Holdings Limited
China Pioneer Pharma is one of the leading comprehensive marketing, promotion and channel management service providers dedicated to imported pharmaceutical products and medical devices in China. The Group was established in 1996, and was listed on the Main Board of the Hong Kong Stock Exchange (HK:1345) on 5 November 2013. The Company has strategically focused on providing comprehensive marketing, promotion and channel management services to small and medium sized overseas suppliers, and is generally the sole provider of such services in China for the relevant products. China Pioneer Pharma runs a diversified range of imported products (substantially all of which are prescription products), covering ophthalmology, pain management, cardiovascular, respiratory, gastroenterology, immunology and other therapeutic areas and a range of medical devices covering four medical specialties, including ophthalmology, odontology and wound care. The Company has also secured marketing, promotion and sales rights for over 20 additional products, which are in the registration process under China Food and Drug Administration for their importation and sales in China. As of 30 June 2015, the Company sold products through its nationwide marketing, promotion and channel management services networks to over 29,000 hospitals and other medical institutions and over 105,000 pharmacies across 31 provinces, municipalities and autonomous regions in China. For more information, visit www.pioneer-pharma.com.
Topic: Clinical Trial Results
Source: China Pioneer Pharma Holdings Limited
Sectors: Daily Finance, Science & Research, Daily News, BioTech, BioTech, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
|
